HUTCHMED (China) Limited (HCM)
NEUTRALFundamental
42
Preço
$12.28
Capitalização de Mercado
$2.12B
Parte 1 · Quanto vale a empresa
Visão Geral
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to treat pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML). In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balanço & Liquidez
Receita
$109M
Últimos 12 meses até o último trimestre divulgado — estimativa a partir de métricas por ação
Resultado Líquido
$91M
Últimos 12 meses até o último trimestre divulgado — estimativa a partir de métricas por ação
Fluxo de Caixa Livre
$-19M
Capital Próprio Total
$1.26B
Passivo Total
$95M
Rácio de Liquidez
5.64
Cobertura de Juros
-
Dívida/EBITDA
-
Resultados Por Ação
Receita & Resultado Líquido
Fluxo de Caixa Livre
Decomposição dos Resultados
Demonstração histórica
Margens ao longo do tempo
A dívida ao longo do tempo
Quanto pesa a dívida
Grelha do crescimento
Crescimento — Receitas
Estimativa de Valor Justo
Valor Justo
$8.56
Preço Atual
$12.28
Margem de Segurança
-43.4%
Intervalo de Valor Justo
$5.56 - $11.56
Métodos de Estimativa
Métricas de Avaliação
Rácio P/E
23.26
ROE
1.5%
Rácio P/B
8.58
P/FCF
-
Margem Bruta
38.7%
ROIC
0.1%
Radar de Rentabilidade
Value Creation (Economic Moat)
ROIC
0.1%
WACC
10.4%
ROIC − WACC
-10.3 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Critérios de Análise Fundamental
Aprovado (8)
- Gross Margin 38.7%
- Debt/Equity ratio
- Current Ratio
- ROE 37.0%
- Revenue Growth 5Y 19.2%
- Analyst Consensus 85% Buy
- Earnings Surprise avg 95.6%
- Net Margin Trend 83.3% vs 6.0%
Reprovado (9)
- Price CAGR -0.72%
- ROIC 0.1%
- P/B Ratio 8.58
- Operating Margin -7.1%
- Positive Free Cash Flow
- Price below Graham Number
- DCF valuation (Unknown)
- Earnings Quality (OCF/NI) 0.04
- Piotroski F-Score 1/9
Indisponível (10)
- EPS data insufficient
- P/FCF NaN
- Dividend Payout NaN%
- CapEx intensity
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- Low reliance on intangibles
- PEG Ratio (need PE > 0 and growth > 0)
- Share Dilution (missing shares data)
Piotroski F-Score
Preocupações financeiras graves
Qualidade dos Resultados
Baixa qualidade: investigar a contabilidade
Diluição de Ações
A recomprar ações. Favorável ao acionista
Governação
Equipa Executiva
| Nome | Cargo | Idade |
|---|---|---|
| Mr. Chig Fung Cheng BEc, CA | Acting CEO, CFO & Executive Director | 58 |
| Dr. Wei-Guo Su B.Sc., Ph.D. | CEO, Chief Scientific Officer & Executive Director (Leave of Absence) | 66 |
| Ms. Yiling Cui | Executive VP & Head of Operations | - |
| Dr. Xinhui Hu Ph.D. | Executive Vice President & Chief Technical Officer | 52 |
| Mr. David Ng | Head of Investor Relations & Capital Strategies | - |
| Mr. Charles George Rupert Nixon | Group General Counsel | 55 |
| Mr. Kin Hung Lee M.B.A. | Senior Vice President of Corporate Management & Communications | 48 |
| Ms. Selina Zhang | Senior Vice President of Global Human Resources | - |
| Dr. Qingmei Wang Ph.D. | Executive Vice President of Business Development & Strategic Alliances | 62 |
| Dr. Thomas Fu | Senior Vice President of Global Quality | - |
Parte 2 · O preço e o momento de entrar
Esta parte não serve para saber se a empresa vale: serve para escolher quando comprá-la, depois que os fundamentos te convenceram. Dentro: análise técnica, potencial, quedas históricas, exposição gama.
Latest News
Recent headlines for HCM, sourced from Markets Gazette.